# Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines

> **NCT02090998** · PHASE4 · TERMINATED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 10 (actual)

## Conditions studied

- Transformed Migraine
- Chronic Daily Headache

## Interventions

- **PROCEDURE:** SPG Block with 5% Lidocaine gel
- **DRUG:** Amitriptyline

## Key facts

- **NCT ID:** NCT02090998
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05
- **Primary completion:** 2020-03-16
- **Final completion:** 2020-03-16
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** no patients during covid pandemic
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02090998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02090998, "Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02090998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*